CN101717430A - 一种重组人组织型纤溶酶原激活剂改构体的纯化方法 - Google Patents
一种重组人组织型纤溶酶原激活剂改构体的纯化方法 Download PDFInfo
- Publication number
- CN101717430A CN101717430A CN200810223907A CN200810223907A CN101717430A CN 101717430 A CN101717430 A CN 101717430A CN 200810223907 A CN200810223907 A CN 200810223907A CN 200810223907 A CN200810223907 A CN 200810223907A CN 101717430 A CN101717430 A CN 101717430A
- Authority
- CN
- China
- Prior art keywords
- liquid
- tween20
- trasylol
- aprotinin
- handled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000000746 purification Methods 0.000 title claims abstract description 23
- 102000013566 Plasminogen Human genes 0.000 title claims abstract description 17
- 108010051456 Plasminogen Proteins 0.000 title claims abstract description 17
- 239000012190 activator Substances 0.000 title claims abstract description 16
- 238000011097 chromatography purification Methods 0.000 claims abstract description 84
- 239000006228 supernatant Substances 0.000 claims abstract description 26
- 239000000047 product Substances 0.000 claims abstract description 19
- 238000001914 filtration Methods 0.000 claims abstract description 16
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 14
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000004440 column chromatography Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 292
- 108010039627 Aprotinin Proteins 0.000 claims description 144
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 134
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 112
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 83
- 239000000872 buffer Substances 0.000 claims description 83
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 83
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 83
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 72
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 72
- 229960004405 aprotinin Drugs 0.000 claims description 72
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 72
- 229940108519 trasylol Drugs 0.000 claims description 72
- 239000002753 trypsin inhibitor Substances 0.000 claims description 72
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 65
- 239000011780 sodium chloride Substances 0.000 claims description 56
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 54
- 239000002953 phosphate buffered saline Substances 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 28
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 18
- 239000004202 carbamide Substances 0.000 claims description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 18
- 150000002460 imidazoles Chemical class 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 12
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 238000012856 packing Methods 0.000 claims description 9
- 241000040710 Chela Species 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 229920002684 Sepharose Polymers 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 9
- 239000012530 fluid Substances 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 58
- 235000011007 phosphoric acid Nutrition 0.000 description 40
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 13
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000002609 medium Substances 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 238000013411 master cell bank Methods 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 230000002537 thrombolytic effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000001938 Plasminogen Activators Human genes 0.000 description 7
- 108010001014 Plasminogen Activators Proteins 0.000 description 7
- 229940127126 plasminogen activator Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 244000309466 calf Species 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000001894 hemadsorption Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000005374 membrane filtration Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 208000006193 Pulmonary infarction Diseases 0.000 description 2
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000033885 plasminogen activation Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000007575 pulmonary infarction Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002384 drinking water standard Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- IDOWTHOLJBTAFI-UHFFFAOYSA-N phenmedipham Chemical compound COC(=O)NC1=CC=CC(OC(=O)NC=2C=C(C)C=CC=2)=C1 IDOWTHOLJBTAFI-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- -1 phytokinin Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102239079A CN101717430B (zh) | 2008-10-09 | 2008-10-09 | 一种重组人组织型纤溶酶原激活剂改构体的纯化方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102239079A CN101717430B (zh) | 2008-10-09 | 2008-10-09 | 一种重组人组织型纤溶酶原激活剂改构体的纯化方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101717430A true CN101717430A (zh) | 2010-06-02 |
CN101717430B CN101717430B (zh) | 2011-09-28 |
Family
ID=42432073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008102239079A Active CN101717430B (zh) | 2008-10-09 | 2008-10-09 | 一种重组人组织型纤溶酶原激活剂改构体的纯化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101717430B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101942429A (zh) * | 2010-08-25 | 2011-01-12 | 广州铭康生物工程有限公司 | 重组人组织型纤溶酶原激活剂TNK突变体rhTNK-tPA的纯化方法 |
CN102408509A (zh) * | 2011-09-07 | 2012-04-11 | 广东工业大学 | 一种纤溶高分子化合物及其合成方法 |
CN104491858A (zh) * | 2014-11-21 | 2015-04-08 | 浙江我武生物科技股份有限公司 | 一种稳定的含有动物毛皮屑变应原的液体药物组合物 |
CN113025604A (zh) * | 2021-03-23 | 2021-06-25 | 重庆中元汇吉生物技术有限公司 | 制备高纯度pic的试剂和方法 |
-
2008
- 2008-10-09 CN CN2008102239079A patent/CN101717430B/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101942429A (zh) * | 2010-08-25 | 2011-01-12 | 广州铭康生物工程有限公司 | 重组人组织型纤溶酶原激活剂TNK突变体rhTNK-tPA的纯化方法 |
CN101942429B (zh) * | 2010-08-25 | 2012-07-04 | 广州铭康生物工程有限公司 | 重组人组织型纤溶酶原激活剂TNK突变体rhTNK-tPA的纯化方法 |
CN102408509A (zh) * | 2011-09-07 | 2012-04-11 | 广东工业大学 | 一种纤溶高分子化合物及其合成方法 |
CN104491858A (zh) * | 2014-11-21 | 2015-04-08 | 浙江我武生物科技股份有限公司 | 一种稳定的含有动物毛皮屑变应原的液体药物组合物 |
CN104491858B (zh) * | 2014-11-21 | 2018-04-13 | 浙江我武生物科技股份有限公司 | 一种稳定的含有动物毛皮屑变应原的液体药物组合物 |
CN113025604A (zh) * | 2021-03-23 | 2021-06-25 | 重庆中元汇吉生物技术有限公司 | 制备高纯度pic的试剂和方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101717430B (zh) | 2011-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021193103A (ja) | ボツリヌス神経毒素を得るためのプロセスおよびシステム | |
JPS62289182A (ja) | 新規なプラズミノゲン活性化物 | |
CN102154253A (zh) | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 | |
JPS59139324A (ja) | 血清非依存性セルラインの確立方法 | |
CN105999244A (zh) | 治疗由骨胶原介导的疾病的组合物及治疗方法 | |
CN101717430B (zh) | 一种重组人组织型纤溶酶原激活剂改构体的纯化方法 | |
CN106929496A (zh) | 一种药用级重组人激肽原酶产业化生产方法 | |
CN102441172A (zh) | 高纯度凝血酶原复合物制品冷冻干燥稳定剂 | |
CN105017410B (zh) | 一种b区部分缺失型重组人凝血因子ⅷ | |
FI76375C (fi) | Foerfarande foer framstaellning av ett fibrinolytiskt enzym. | |
CN100465270C (zh) | 沙蚕蛋白酶及其分离提取纯化方法和应用 | |
CN111995686A (zh) | 一种具有抗血管生成活性的药物及其制备方法 | |
KR100508043B1 (ko) | rDSPAα1의 제조방법 | |
CN101709083B (zh) | 一种来自蝎尾的纤溶活性蛋白及其制备方法和应用 | |
EA026017B1 (ru) | Фармацевтические композиции тенектеплазы | |
CN107760662B (zh) | 一种人纤维蛋白溶解酶的制备方法 | |
CN101139578A (zh) | 具有抗血小板聚集和纤溶活性的双功能葡激酶突变体、应用及其制备方法 | |
CN103789291A (zh) | 一种重组大肠杆菌发酵液中分离纯化重组人尿激酶原的制备工艺 | |
JPS6322187A (ja) | ヒトプラスミノ−ゲン活性化因子の製造法 | |
CN114480353B (zh) | 一种制备重组人奥克纤溶酶的方法 | |
CN1446912A (zh) | 一种重组葡激酶冻干制剂、制备方法和应用 | |
RU2326944C2 (ru) | Способ получения и препарат аналога рекомбинантного интерферона гамма человека | |
CN110343170A (zh) | 纤溶酶抑制剂rPI-T1的分离纯化方法 | |
CN1274817C (zh) | 抗尿激酶原单克隆抗体杂交瘤细胞系及其应用 | |
GB2153366A (en) | Plasminogen activator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100602 Assignee: SHIMAOTIANJIE PHARMACEUTICAL (JIANGSU) CO.,LTD. Assignor: BEIJING SHIMAODONGRUI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Contract record no.: 2016990000066 Denomination of invention: Purification method of recombinant human tissue type profibrinolysin activator modified body Granted publication date: 20110928 License type: Exclusive License Record date: 20160304 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20160322 Contract record no.: 2016990000066 License type after: Exclusive license License type before: exclusive license |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SHIMAOTIANJIE PHARMACEUTICAL (JIANGSU) Co.,Ltd. Assignor: BEIJING SHIMAODONGRUI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Contract record no.: 2016990000066 Date of cancellation: 20210610 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kind of purification method of recombinant human tissue-type plasminogen activator modified body Effective date of registration: 20220920 Granted publication date: 20110928 Pledgee: THE PLACE INVESTMENT GROUP Co.,Ltd. Pledgor: BEIJING SHIMAODONGRUI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Registration number: Y2022990000651 |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20230428 Granted publication date: 20110928 |
|
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20230721 Granted publication date: 20110928 |